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Introduction: Intravenous fish oil (FO) lipid emulsions (LEs) are rich in ω-3 polyunsaturated fatty acids, which exhibit
anti-inflammatory and immunomodulatory effects. We previously demonstrated that FO-containing LEs may be able
to decrease mortality and ventilation days in patients who are critically ill. Since 2014, several additional randomized
controlled trials (RCTs) of FO-containing LEs have been published. Therefore, the purpose of this systematic review
was to update our previous systematic review with the aim of elucidating the efficacy of FO-containing LEs on clinical
outcomes of patients who are critically ill.
Methods: We searched electronic databases from 1980 to 2014. We included four new RCTs conducted in critically ill
adult patients in which researchers evaluated FO-containing LEs in parenterally or enterally fed patients.
Results: A total of 10 RCTs (n = 733) met inclusion criteria. The mean methodological score was 8 (range, 3 to 12). No
effect on overall mortality was found. When we aggregated the results of five RCTs in which infections were reported,
we found that FO-containing LEs significantly reduced infections (risk ratio (RR) = 0.64; 95% confidence interval (CI), 0.44
to 0.92; P = 0.02; heterogeneity I2 = 0%). Subgroup analysis demonstrated that predominantly enteral nutrition–based
trials showed a tendency toward a reduction in mortality (RR = 0.69; 95% CI, 0.40 to 1.18; P =0.18; heterogeneity
I2 =35%). High-quality trials showed a significant reduction in hospital length of stay (LOS) (weighted mean
difference = −7.42; 95% CI, −11.89 to −2.94; P = 0.001), whereas low-quality trials had no effect (P = 0.45). The results of
the test for subgroup differences in hospital LOS was significant (P = 0.001).
Conclusion: FO-containing LEs may be associated with a reduction in infections and also could be associated with a
reduction in duration of ventilation and hospital LOS. Further large-scale RCTs are warranted and should be aimed at
consolidating potential positive treatment effects.Introduction
Lipid emulsions (LEs), which are an integral part of a
parenteral nutrition (PN) regimen, provide exogenous
fatty acids, which are commonly used by cells as an
energy-dense source of fuel calories (approximately 9
kcal/g), cell membrane components and biologically ac-
tive substrates [1-3]. In patients who are critically ill,
commonly used LEs have provided long-chain triglycer-
ides (LCTs), particularly soybean oil (SO), with a high
percentage of ω-6 polyunsaturated fatty acids (PUFAs;* Correspondence: wmanzanares@adinet.com.uy
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unless otherwise stated.18:2 ω-6) [4]. Nonetheless, over the last few decades,
several different SO-sparing strategies have been devel-
oped, which are defined as alternative oil-based LEs. Fish
oil (FO)-containing LEs are a type of alternative LE that
are high in ω-3 PUFAs (18:3 ω-3). Examples are eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA)
[5]. According to the capacity of EPA and DHA to
modulate the synthesis of eicosanoids, the activity of
nuclear receptor and nuclear transcription factors, and
the production of resolvins, these fatty acids have long
been recognized as having anti-inflammatory and immu-
nomodulatory effects [6]. In a secondary analysis of data
from the International Nutrition Survey, Edmunds et al.
[7] demonstrated that FO-containing LEs were able to
reduce the duration of mechanical ventilation (MV) andntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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pared with SO-based LEs. Over the last few years, there
have been several RCTs on FO-containing LEs in pa-
tients who are critically ill in which investigators
reported relevant clinical outcomes, which have been in-
cluded in previous meta-analyses [8-10].
In 2012, in a systematic review and meta-analysis,
Pradelli et al. [8] concluded that in elective surgery and
critically ill patients, parenteral FO-containing LEs were
associated with a significant reduction in infections, al-
though Palmer et al. [9], in another systematic review,
were unable to find similar results in ICU patients.
In 2013, after aggregating six RCTs evaluating the ef-
fect of parenteral FO-containing LEs on relevant clinical
outcomes in a heterogeneous ICU patient population
[10], we demonstrated that FO-containing LEs may be
able to decrease mortality (risk ratio (RR), 0.71; 95%
confidence interval (CI), 0.49 to 1.04; P = 0.08) and also
reduce the duration of MV (weighted mean difference
(WMD) = −1.41; 95% CI, −3.43 to 0.61; P = 0.17) [10].
Nonetheless, since 2014, several RCTs evaluating clinical
effects of FO-containing LEs as compared with other
LEs (SO, medium-chain triglycerides (MCTs) and/or
LCTs or olive oil (OO)) in ICU patients being treated
with PN- and EN-based strategies have been published.
Therefore, with the aim of elucidating the efficacy of
parenteral FO-containing LEs in patients who are critic-
ally ill, we performed an update of our previous system-
atic review and meta-analysis of the literature.
Methods
Search strategy and study identification
A literature review was conducted to identify in
MEDLINE, Embase, CINAHL, the Cochrane Central
Register of Controlled Trials and the Cochrane Database
of Systematic Reviews all relevant RCTs published be-
tween 1980 and November 2014. The following keywords
or medical subject headings were used: “randomized,”
“clinical trial,” “nutrition support,” “artificial feeding,”
“parenteral nutrition,” “pharmaconutrition,” “omega-3 fatty
acids,” “fish oils,” “lipid emulsions,” “intensive care,” “crit-
ical illness” and “critically ill.” We did not restrict our
search to only articles written in English.
Eligibility criteria
Trials were included if they met the following
characteristics:
1. Type of study: RCT with a parallel group.
2. Population: critically ill adult patients (≥18 years of
age), defined as patients admitted to an ICU. If the
study population was unclear, we considered a
mortality rate higher than 5% in the control group
to be consistent with critical illness. We excludedRCTs performed in elective surgery patients (such as
open-heart surgery patients) even if patients were
cared for in an ICU in the postoperative period.
3. Intervention: intravenous FO-containing LEs as part
of PN or as a pharmaconutrient strategy (enterally
fed patients).
4. Control: EN, PN with SO-based LEs or a non-FO-
based LE, as well as saline solution. Non-FO LEs
and saline solution were defined as non-FO lipids or
non-FO strategies.
5. Outcomes: Overall mortality was the primary
outcome for this meta-analysis. Secondary outcomes
were infections, ICU and hospital length of stay
(LOS) and MV days. As in previous meta-analyses
conducted by our group, we excluded those trials
that reported only nutrition, biochemical, metabolic
or immunologic outcomes. The methodological
quality of the included trials was assessed in duplicate
independently by two reviewers using a data
abstraction form with a scoring system [11] from 0 to
14 according to the following criteria:
a. The extent to which randomization was
concealed
b. Blinding
c. Analysis based on the intention-to-treat (ITT)
principle
d. Comparability of groups at baseline
e. Extent of follow-up
f. Description of treatment protocol
g. Cointerventions
h. Definition of clinical outcomes
Consensus between both reviewers on the individual
scores of each of the categories was obtained. We
attempted to contact the authors of included studies and
requested additional information not contained in pub-
lished articles. We designated studies as level I if all of the
following criteria were fulfilled: concealed randomization,
blinded outcome adjudication and an ITT analysis, which
are the strongest methodological tools to reduce bias. A
study was considered as level II if any one of the above-
described characteristics were unfulfilled.
Data synthesis
The primary outcome of the systematic review was mor-
tality (hospital mortality or if not reported, 28 days or
ICU mortality). The definitions of infectious complica-
tions as defined by authors of individual trials were used.
We analyzed data using RevMan 5.3 (Cochrane IMS,
Oxford, UK) with a random effects model. We com-
bined data from all trials to estimate the pooled risk
ratio (RR) with 95% confidence intervals (CIs) for mor-
tality and infections and overall weighted mean differ-
ence (WMD) with 95% confidence intervals for LOS
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Haenszel estimator, and WMDs were estimated by the
inverse variance approach. The random effects model of
DerSimonian and Laird was used to estimate variances
for the Mantel-Haenszel [12] and inverse variance esti-
mators. RRs were undefined and excluded for studies
with no event in either arm. Heterogeneity was tested by
a weighted Mantel-Haenszel χ2 test and quantified by
the I2 statistic as implemented in RevMan. Differences
between subgroups were analyzed using the test of sub-
group differences described by Deeks et al. [13], and the
results expressed using the P-values.
The possibility of publication bias was assessed by gen-
erating funnel plots and testing asymmetry of outcomes
using methods proposed by Rucker et al. [14]. We con-
sidered P <0.05 to be statistically significant and P <0.20
as an indicator of trend.
Subgroup analysis
We performed a predefined subgroup analysis to assess
a number of possible influences on the effects of intra-
venous FO-containing LEs on clinical outcomes. We
first examined the effect of parenteral FO-containing
LEs in the context of PN (PN-based trials) versus pre-
dominantly EN-based trials [15-18], which included EN
alone, EN with PN, EN with oral (PO) or EN, PN and
PO together. In addition, as the trial quality can influ-
ence clinical findings, we postulated that trials with
lower quality (defined as level II studies) may demon-
strate a greater treatment effect than those trials with
higher quality (level I studies), which were previously
defined.Figure 1 Flow diagram of the literature search according to the Quality ofResults
A total of 54 relevant citations were identified in the
search of electronic bibliographic databases and a review
of reference lists in related articles. We excluded 44 tri-
als for the following reasons: 25 trials [19-43] did not in-
clude ICU patients (mostly elective surgery and cancer
patients); 10 trials [44-53] did not evaluate clinically im-
portant outcomes; 2 trials [54,55] were published as ab-
stracts, and we were unable to obtain the data from the
authors to complete our data abstraction process; 2 trials
[56,57] were conducted in a pediatric population; 2 trials
[58,59] had a short duration of intervention (a single in-
fusion during the study period); and 3 articles [8,9,60]
were systematic reviews and meta-analyses (Figure 1).
In the end, ten RCTs [15-18,61-66], including four
new trials [17,18,65,66] published since our last meta-
analysis, met the inclusion criteria and were finally in-
cluded in this systematic review (see Tables 1 and 2).
The ten trials comprised an aggregate total of 733 pa-
tients. There was considerable heterogeneity in the inter-
ventions tested in these trials. Among RCTs in PN-fed
patients, three trials [63-65] compared a LCT + MCT +
FO LE with an MCT + LCT LE, two trials [61,62] com-
pared a FO + LCT LE with a LCT LE and one trial [66]
compared a FO + OO LE with an OO-containing LE.
Among the four RCTs in which investigators evaluated
predominantly EN-fed patients [15-18], one trial [16]
compared supplementation of EN or PO diet with a paren-
teral FO-containing LE to EN or PO diet with intravenous
normal saline, one trial [15] compared supplementation of
EN with a parenteral FO-containing LE to EN alone, one
trial [17] compared supplementation of EN, PN or PO dietReporting of Meta-analyses statement [72].
Table 1 Randomized clinical trials evaluating parenteral fish oil–containing lipid emulsions in critically ill patientsa
Study Population Methods (score) Intervention Mortality (%)b Infections (%)c
FO
Grecu et al., 2003d [62] Patients with
abdominal sepsis
C.Random: Yes PN + Omegaven (10% FO; Fresenius Kabi,
Bad Homburg, Germany) plus LCT vs.
PN with LCT
Omegaven + LCT LCT Omegaven LCT
N =54 ITT: Yes ICU ICU VAP VAP
(15 of 54 in ICU) Blinding: Double 2/28 (7) 3/26 (12) 0/8 1/7 (14)
(12)
Friesecke et al., 2008 [63] Medical ICU patients C.Random: Yes PN + Lipofundin (B Braun, Melsungen,
Germany) MCT (50% LCT + 50% MCT) +
Omegaven (10% FO) vs. PN with
Lipofundin MCT (50% LCT + 50% MCT)
MCT + LCT + FO LCT + MCT MCT + LCT + FO LCT + MCT
N =166 ITT: Yes 28 days 28 days 10/83 (12) 11/82 (13)
Blinding: Double 18/83 (22) 22/82 (27)
(10)
Wang et al., 2009 [61] Severe acute pancreatitis
patients in ICU
C.Random: No PN + Omegaven (10% FO) plus
Lipovenos (LCT, soybean oil; Fresenius
Kabi) (ω3:ω6 ratio was 1:4) vs. PN with
Lipovenos (LCT, soybean oil). Both
received same amounts of lipids
(1 g/kg/day)
Omegaven LCT Omegaven LCT
N =56 ITT: Yes ICU ICU 6/28 (21) 9/28 (32)
Blinding: Double 0/28 (0) 2/28 (7)
(11)
Barbosa et al., 2010 [64] ICU patients with SIRS
or sepsis requiring PN
C.Random: Yes PN + Lipolus (50% MCT, 40% LCT soybean
oil, 10% FO; B Braun) vs. PN with NuTRIflex
Lipid Special (50% MCT, 50% LCT, soybean
oil; B Braun). Both received same amounts
of lipids (about 1 g/kg/day)
MCT + LCT + FO MCT + LCT MCT + LCT + FO MCT + LCT
N =25 ITT: Yes 5 days 5 days NR NR
Blinding: Single 2/13 (15) 1/10 (10)
(10) 28 days 28 days
4/13 (31) 4/10 (40)
Gupta et al., 2011 [15] ICU patients with
suspected ARDS
C.Random: Yes EN (standard diet) + Omegaven 10%
(ω3:ω6 ratio was 1:4) vs. EN
(standard diet)
Omegaven Standard NR NR
N =61 ITT: Yes ICU EN
Blinding: Double 7/31 (23) ICU
(9) Hospital 13/30 (43)
9/31 (29) Hospital
14/30 (47)
Khor et al., 2011 [16] ICU patients with severe
sepsis/septic shock
C.Random: Yes Supplementation with 100 ml of 10%
Omegaven (10 g of refined FO, EPA 12.5 to
28.2 g/L, DHA 14.4 to 30.9 g/L) vs. 100 ml
of 0.9% normal saline
NR NR NR NR












Table 1 Randomized clinical trials evaluating parenteral fish oil–containing lipid emulsions in critically ill patientsa (Continued)
Burkhart et al., 2013 [18] ICU patients
with sepsis
C.Random: ? 2 ml/kg/day Omegaven vs. no parenteral
FO. Both groups received EN and/or PN
without added FO at the discretion of
the clinician.
Omegaven No Omegaven NR NR
N =50 ITT: Yes Hospital Hospital
Blinding: Single
(assessor)
13/25 (52) 13/25 (52)
(8)
Grau-Carmona et al., 2014 [65] Medical and surgical
patients requiring PN
C.Random: Yes PN + Lipoplus (50% MCT, 40% LCT soybean
oil, 10% FO; B Braun) vs. PN + Lipofundin
(50% LCT + 50% MCT)
MCT + LCT + FO MCT + LCT ICU MCT + LCT + FO MCT + LCT
N =175 ITT: Yes ICU 16/78 (20.5) 17/81 (21) 29/78 (37.2)
Blinding: Double 26/81 (32.5) Hospital
(10) Hospital 6/78 (9.7)
6/81 (11.1) 6 months
6 months 2/78 (3.6)
2/81 (4.3)
Gultekin et al., 2014 [66] ICU patients
needing TPN
C.Random: ? PN + Omegaven (10% FO) plus ClinOleic
(80% olive oil, 20% soybean oil; Baxter
Healthcare, Compton, UK) vs. PN + ClinOleic
Omegaven + olive oil Olive oil NR NR
N =58 ITT: Other Unspecified Unspecified
Blinding: Double 8/16 (50) 7/16 (44)
(3)
Hall et al., 2014 [17] ICU patients
with sepsis
C.Random: ? Omegaven dosed at 0.2 g of FO/kg/day
given at a rate of 0.05 g of FO/kg/day vs. no
FO. Both groups received EN and/or PN at
the discretion of the clinician.
Omegaven No Omegaven Omegaven No Omegaven
N =60 ITT: Yes Hospital Hospital 3/30 (10) 5/30 (16.7)
Blinding: No 4/30 (13.3) 9/30 (30)
(9) 28 days 28 days
4/30 (13.3) 8/30 (26.7)
aThese studies compared fish oil (ω-3)–containing emulsions in parenteral nutrition–fed patients with long-chain triglycerides or long-chain triglycerides + medium-chain triglycerides. ARDS, Acute respiratory distress
syndrome; C.Random, Concealed randomization; DHA, Docosahexaenoic acid; EPA, Eicosapentaenoic acid; FO, Fish oil; ICU, Intensive care unit; ITT, Intention to treat; LCT, Long-chain triglycerides; LE, Lipid emulsion;
MCT, Medium-chain triglycerides; NA, Non-attributable; NR, Non-reported; PN, Parenteral nutrition; SIRS, Systemic inflammatory response syndrome; TPN, Total parenteral nutrition; VAP, Ventilator-associated pneumonia;











Table 2 Outcomes of included trials on fish oil strategies using lipid emulsionsa
Study LOS in days Ventilator days Oth
FO
Grecu et al., 2003b [62] Omegaven
(Fresenius Kabi, Bad Homburg, Germany)
LCT Omegaven LCT Ome ven LCT
ICU ICU 2.83 ± 1.62 (8) 5.23 ± 2.80 (7) Pati s undergoing reoperation for septic episode
3.32 ± 1.48 (8) 9.28 ± 3.08 (7) 2/28 ) 8/26 (31)
Hospital Hospital
11.68 ± 2.04 (28) 20.46 ± 3.27 (26)
Friesecke et al., 2008 [63] FO LCT LCT + MCT + FO LCT + MCT LCT CT + FO LCT + MCT
ICU ICU 22.8 ± 22.9 (83) 20.5 ± 19.0 (82) Urin tract infections
28 ± 25 (83) 23 ± 20 (82) 6/83 ) 4/82 (5)
Cath er-related infections
1/83 ) 3/83 (4)
Tota N energy intake (kcal/kg)
22.2 .5 21.6 ± 5.6
Wang et al., 2009 [61] NR NR NR NR Ome ven LCT
Surg y of infected pancreatic necrosis
3/28 1) 6/28 (21)
Barbosa et al., 2010 [64] MCT + LCT + FO MCT + LCT MCT + LCT + FO MCT + LCT MCT LCT+ FO MCT + LCT
ICU ICU 10 ± 14.4 (13) 11 ± 12.64 (10) 2,05 418 kcal 1,857 ± 255 kcal
12 ± 14.4c (13) 13 ± 12.6c (10)
Hospital Hospital
22 ± 25.2c (13) 55 ± 50.6c (10)
Gupta et al., 2011 [15] Omegaven Standard EN Omegaven Standard EN
ICU ICU 11.78 ± 10.63 (31) 10.71 ± 14.55 (30)
15.96 ± 7.57 (31) 15.88 ± 6.47 (30)
Hospital Hospital
21.5 ± 13.49 (31) 26.63 ± 18.22 (30)
Khor et al., 2011 [16] Omegaven Saline Omegaven Saline
ICU ICU 13.0 ± 10.1 (9) 11.6 ± 9.5 (5)
10.3 ± 8.4 (14) 8.4 ± 6.5 (13)
Hospital Hospital

























Table 2 Outcomes of included trials on fish oil strategies using lipid emulsionsa (Continued)
Burkhart et al., 2013 [18] Omegaven No Omegaven NR NR Omegaven No Omegaven
ICU ICU Subsyndromal delirium
5 (3 to 22) 6 (2 to 33) 5 (25) 6 (29)
Sepsis associated delirium
15 (75) 15 (71)
Grau-Carmona et al., 2014 [65] MCT + LCT + FO MCT + LCT MCT + LCT + FO MCT + LCT MCT + LCT+ FO MCT + LCT
ICU ICU 8.41 ± 6.61 9.2 ± 6.0 Parenteral lipid intake [(g/kg BW)/d]
18.9 ± 15.5 21.8 ± 20.9 1.04 ± 0.12 1.05 ± 0.13
Hospital Hospital PN kcal
41.1 ± 41.0 42.5 ± 28.5 1,737 ± 353 1,782 ± 312
Gultekin et al., 2014 [66] Omegaven + olive Olive oil NR NR Omegaven + olive oil Olive oil
Hospital Hospital
31.6 ± 4.3 30.6 ± 4.3 27.5 ± 1.5 kcal/kg/day 15.8 ± 1.5 kcal/kg/day
1.3 ± 0.2 g protein/kg/day 1.1 ± 0.1 g protein/kg/day





8.8 ± 7.7 12.3 ± 12.4
Hospital Hospital
26.7 ± 18.2 33.5 ± 30.4
aThese studies compared fish oil (ω-3)–containing emulsions in parenteral nutrition–fed patients vs. LCT or LCT + MCT. EN, Enteral nutrition; FO, Fish oil; ICU, Intensive care unit; LCT, Long-chain triglycerides;
MCT, Medium-chain triglycerides; ITT, Intention to treat; NR, Not reported. bData obtained from author, 8 of 28 in Omegaven (Fresenius Kabi, Bad Homburg, Germany) group and 7 of 26 in LCT group were in the ICU.
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diet alone, and one trial [18] compared supplementation
of EN or PN with a parenteral FO-containing emulsion to
EN or PN alone. We reached 100% agreement for in-
clusion of trials in the present review. The mean meth-
odological score of all trials was 9 (range, 3 to 12).
Randomization was concealed in six (60%) of the ten
trials, ITT analysis was performed in eight trials (80%)
and seven trials (70%) were double-blinded. There were
five level I studies [15,61-64] and five level II studies
[16-18,61,66]. The details of the methodological quality
of the individual trials are shown in Table 1.
Meta-analyses of primary and secondary outcomes
Primary outcome
Mortality When the data from nine RCTs [15,17,18,61-66]
evaluating mortality as one of the outcomes were aggre-
gated, FO-containing strategies did not achieve a statisti-
cally significant reduction in mortality (RR = 0.90; 95% CI,
0.67 to 1.20; P = 0.46; heterogeneity I2 = 0%) (see Figure 2).
Heterogeneity was not significant (P = 0.29).
Secondary outcomes
Infectious complications When the results of five RCTs
[17,61-63,65] that reported infectious complications were
aggregated, FO-containing LEs significantly reduced infec-
tions (RR = 0.64; 95% CI, 0.44 to 0.92; P = 0.02; heterogen-
eity I2 = 0%) (see Figure 3). Similarly, after excluding the
Grecu et al. [62] study because the authors reported only
ventilator-associated pneumonia (VAP), the same effect
was shown (RR = 0.65; 95% CI, 0.44 to 0.94; P = 0.02; het-
erogeneity I2 = 0%).
Mechanical ventilation The aggregation of six RCTs
[15,16,62-65] on FO-containing LEs in which the re-
searchers reported on MV showed a trend toward reduc-
tion in the number of days on MV (WMD, −1.14; 95%
CI, −2.67 to 0.38; P = 0.14; heterogeneity I2 = 0%) (see
Figure 4).
Hospital length of stay When the data from seven
RCTs [15-17,62,64-66] in which researchers reported on
hospital length of stay were aggregated, FO-containing
strategies showed a trend toward reduction in hospital
LOS, without reaching statistical significance (WMD =
−3.71; 95% CI, −9.31 to 1.88; P = 0.19) (see Figure 5).
The heterogeneity was significant (P <0.00001; I2 = 87%).
ICU length of stay The seven RCTs [15-17,62-65] evalu-
ating ICU length of stay were aggregated, but we did not
find any effects related to FO-containing LEs in paren-
terally fed patients (WMD = −1.42; 95% CI, −4.53 to
1.69; P = 0.37) (see Figure 6). However, the heterogeneity
analysis was statistically significant (P = 0.01; I2 = 63%).Subgroup analyses
Parenteral nutrition–based trials versus predominantly
enteral nutrition–based trials
In six trials, researchers investigated the administration
of FO-containing LEs in parenterally fed patients [61-66],
whereas in four trials [15-18], parenteral FO supplementa-
tion was studied in the context of patients receiving
predominantly EN. There were no significant differences
in any endpoint between trials of PN- versus EN-based
nutritional strategies. However, in those EN-based trials
[15,17,18] in which patients received intravenous FO-
containing LEs, this pharmaconutrient strategy showed a
tendency toward a reduction in mortality (RR = 0.69; 95%
CI, 0.40 to 1.18; P = 0.18; heterogeneity I2 = 35%) (see
Figure 2). When we examined the effect of FO-containing
LEs in PN-based trials versus predominantly EN-based tri-
als, the test for subgroup differences on overall mortality
showed a trend (P = 0.19).
Effect of study quality on outcomes
Similarly to low-quality trials [17,18,61,66], the higher-
quality trials [15,62-65] did not show any effect on mortal-
ity (P = 0.58 in both subgroups). Nonetheless, a statistically
significant effect of FO-containing LEs on the reduction of
infections was shown in the higher-quality trials [62,63,65]
(RR = 0.64; 95% CI, 0.42 to 0.97; P = 0.04; heterogeneity
I2 = 0%), whereas trials with lower methods scores did
not show any significant effect (RR = 0.65; 95% CI, 0.31
to 1.35; P = 0.25; heterogeneity I2 = 0%). However, the
overall tests for significance did not reveal statistically sig-
nificant differences between these subgroups (P = 0.97).
The effect of study quality on MV did not show any
significant effect, although one low-quality trial [16] ex-
plored this outcome. The test for subgroup differences
on MV days was not significant (P = 0.64). With regard
to hospital LOS, higher-quality trials [15,62,64,65] showed
a significant reduction (WMD = −7.42; 95% CI, −11.89 to
−2.94; P = 0.001), although low-quality trials had no effect
(P = 0.45). The test for subgroup differences in hospital
LOS showed a significant difference between both sub-
groups (P = 0.001). Finally, there were no differences be-
tween high- and low-quality trials with regard to ICU
LOS (P = 0.86).
Discussion
Systemic inflammation and immune dysfunction are two
key features in critical illness. In this context, it may be
that provision of parenteral FO-containing LEs in ICU
patients receiving PN or EN (pharmaconutrient strategy)
represents a promising and attractive therapeutic option.
We have updated our previous systematic review by
evaluating the effects of FO-containing LEs on relevant
clinical outcomes in ten eligible RCTs [15-18,61-66] in-
volving critically ill patients. The main findings of our
Figure 3 Effects on infections of parenteral fish oil containing emulsions (n =5). CI, Confidence interval; EN, Enteral nutrition; LCT, Long-chain
triglycerides; MCT, Medium-chain triglycerides; M-H, Mantel-Haenszel test; PN, Parenteral nutrition.
Figure 2 Effects on mortality of fish oil lipid emulsion strategies (n =9). CI, Confidence interval; EN, Enteral nutrition; LCT, Long-chain triglycerides;
MCT, Medium-chain triglycerides; M-H, Mantel-Haenszel test; PN, Parenteral nutrition.
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Figure 4 Effects on mechanical ventilation days of parenteral fish oil containing emulsions (n =6). CI, Confidence interval; EN, Enteral nutrition;
IV, Inverse Variance; M-H, Mantel-Haenszel test; PN, Parenteral nutrition; SD, Standard deviation.
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fections and may be associated with a tendency toward
fewer MV days compared with SO-based strategies or
administration of other alternative LEs in ICU patients.
Nonetheless, contrary to our previous findings [10], we
did not find a tendency toward reduced mortality, al-
though in EN-based trials FO-containing LEs as pharma-
conutrition may be associated with a tendency toward
reduced mortality. The benefit in terms of improvementFigure 5 Effects on hospital length of stay of parenteral fish oil containing
IV, Inverse Variance; M-H, Mantel-Haenszel test; PN, Parenteral nutrition; SD,in recovery times, as indicated by the tendency toward a
reduction in MV days and hospital LOS, may be due to re-
duced infections, generally or specifically a lower inci-
dence of VAP, which is a frequent cause of infection in
mechanically ventilated patients and is associated with
significant attributable morbidity and mortality [67]. The
presently reported results notwithstanding, these out-
comes should be explored in further well-conducted and
adequately powered RCTs.emulsions (n =7). CI, Confidence interval; EN, Enteral nutrition;
Standard deviation.
Figure 6 Effects on ICU length of stay of parenteral fish oil containing emulsions (n =7). CI, Confidence interval; EN, Enteral nutrition;
IV, Inverse Variance; M-H, Mantel-Haenszel test; PN, Parenteral nutrition; SD, Standard deviation.
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most updated evaluation of the overall effects of FO-
based PN strategies in the critically ill. In addition, it is
pertinent for intensive care as, according to our inclu-
sion criteria, it contains only RCTs evaluating clinical
outcomes in ICU patients. Unfortunately, with the ex-
ception of two trials [63,65], most trials included in this
systematic review were relatively small studies with
fewer than 100 patients and therefore were inadequate
to detect a clinically important treatment effect of FO-
containing LEs on mortality. However, the advantage of
meta-analytic techniques is that they can combine data
across studies to discern a more precise treatment effect.
In addition, given the wide variety of clinical diagnoses
and the heterogeneous population of ICU patients in-
cluded in this systematic review (sepsis, severe sepsis
and/or septic shock, trauma, cancer, pancreatitis, and
systemic inflammatory response syndrome), the results
and conclusions may be applied to a broad and hetero-
geneous group of ICU patients.
Since 2012, different meta-analyses [8,9,60] on FO-
enriched PN have been published. The differences with
our present review are largely due to the variations in
the studies included in the reviews. In 2012, Pradelli et al.
[8] statistically aggregated 23 RCTs in elective surgery and
critically ill patients, and, similarly to our findings, they
demonstrated that FO-based PN strategies were associ-
ated with a significant reduction in infections (RR = 0.61;
95% CI, 0.45 to 0.84; P = 0.002). Furthermore, Pradelli
et al. [8] showed a statistically and clinically significant
effect on LOS, both in the ICU (WMD = −1.92; 95% CI,−3.27 to −0.58; P = 0.005) and in the hospital (WMD =
−3.29; 95% CI, −5.13 to −1.45; P = 0.0005), although no ef-
fect on overall mortality was found. The results regarding
infections in the Pradelli et al. study [8] are very similar to
our findings, although the inclusion criteria were different,
as Pradelli et al. included ten trials in adult patients under-
going elective major abdominal surgery and not admitted
to the ICU (n = 740). Meanwhile, after aggregating nine
RCTs on FO-containing LEs in ICU patients receiving PN,
Palmer et al. [9] were unable to demonstrate any signifi-
cant effect on infectious complications (RR = 0.78; 95%
CI, 0.43 to 1.41; P = 0.41) or on mortality and ICU LOS.
Palmer et al. [9] included studies published by Wang et al.
in 2008 [33] and 2009 [61]. However, we excluded the
2008 Wang et al. trial [33] because we included a later
version of the study that included more patients [61].
Additionally, we excluded two unpublished trials, one by
Leiderman et al. [54] and one by Ignatenko et al. [55].
Both of these trials [54,55] were included in the prior
meta-analyses, but they are published only as abstracts,
and we were not able to obtain data from the investigators
necessary to have these trials included in our review.
In 2014, Chen et al. [60] summarized 12 RCTs that
administered ω-3 PUFAs through enteral or parenteral
routes in ICU patients and showed a tendency toward a
reduction in mortality (RR = 0.82, 95% CI, 0.62 to 1.09;
P = 0.18), although the effect on other clinical out-
comes was not analyzed [60].
Is it plausible that FO-containing LEs reduce infec-
tions? According to current knowledge, ω-3 PUFAs have
different effects on the function and gene expression of
Manzanares et al. Critical Care  (2015) 19:167 Page 12 of 15the immune cells, affecting cellular and humoral immun-
ity [2-4,6], which may explain their effects on infections in
the critically ill. DHA generates protectins, D-series resol-
vins and maresins, whereas EPA generates E-series resol-
vins. The immunomodulatory effects of EPA and DHA, in
contrast to the ω-6 PUFAs, have been largely recognized
for the ability of ω-3 PUFAs to modify leukocyte activity,
decrease cell membrane fluidity, alter the production of
bioactive mediators and cell signaling, and modulate sys-
temic inflammation by inhibition of cytokine release
[2,68]. Intravenous infusion of FO-containing LEs rapidly
leads to an incorporation of ω-3 PUFAs in leukocyte cell
membrane phospholipids, leading to a reduced production
of proinflammatory cytokines because of a higher ratio of
ω-3 to ω-6 PUFAs [2,6].
In 2008, Liang et al. [32] supplemented patients
undergoing radical colorectal cancer resection with FO-
enriched PN and showed a reduction in interleukin (IL)-
6, a high CD4+/CD8+ ratio, and higher CD3+ and CD4+
lymphocytes. These findings suggest that supplementa-
tion of EPA and DHA by the parenteral route may sup-
port immunocompetent cells in seriously ill surgical
patients. Meanwhile, Mayer et al. [52] demonstrated a
significant improvement in neutrophil function in pa-
tients receiving FO-containing LEs, including leukotri-
ene generation and respiratory burst. More recently, in a
rat model of sepsis, Terashima et al. [69] demonstrated
that FO-enriched PN may regulate neutrophil functions,
restoring delayed apoptosis, which was associated with
an increase in leukotriene B5 (LTB5) production from
peritoneal neutrophils. Hecker et al. [70], in a very elegant
murine model of acute respiratory distress syndrome,
demonstrated, among other findings, that parenteral FO
decreased leukocyte invasion, protein leakage, myeloper-
oxidase activity, and cytokine production in the alveolar
space. Therefore, they have speculated that ω-3 PUFAs
could be beneficial in reducing pulmonary inflammatory
complications such as VAP [70]. All of these experimental
findings may explain, at least in part, the anti-inflammatory
and immunomodulatory effects of ω-3 PUFAs seen in
clinical practice.
In sepsis, parenteral FO-containing LEs can result in
favorable changes to inflammation and immunity by
minimizing inflammation and maximizing resolution of
inflammatory response and thus improving patient out-
comes. However, resolvin D1 produced from DHA has
several actions that stop polymorphonuclear neutrophil
infiltration and inhibit microglial cells from expressing
inflammatory cytokines in in vitro animal models. In
addition, resolvin E1 decreases leukocyte infiltration in-
duced by tumor necrosis factor (TNF)-α [71]. Therefore,
oversuppression may potentially lead to immuno-
suppression, although there are conflicting data on the
effect on cytokine expression and immunologicalmarkers, as no documented reports of negative
hemostatic outcomes from FO-containing LEs in sepsis/
severe sepsis have been published.
The investigators in the clinical trials included in our
systematic review evaluated mechanistic effects of FO-
containing LEs. Hall et al. [17] demonstrated a signifi-
cant reduction in C-reactive protein (CRP) mean values
in the FO-enriched PN group, although Burkhart et al.
[18] were unable to find differences in IL-6, IL-8, IL-10
and CRP levels between patients supplemented and
non-supplemented with FO. Meanwhile, after comparing
two alternative LEs, Gultekin et al. [66] found a significant
reduction in LTB4 and CRP levels in FO-supplemented
patients, whereas IL-6 and TNF-α levels were not different
between groups. Previously, Barbosa et al. [64] demon-
strated a significant reduction in plasma IL-6 and IL-10
levels in the FO group. Similarly, Wang et al. [61] showed
an increase in IL-10 levels and human leukocyte antigen
DR expression, as well as a concomitantly significant re-
duction in CRP levels, in patients with severe acute
pancreatitis.
The strength of our meta-analysis is based on the fact
that, as in previous meta-analyses, we used several
methods to reduce bias (comprehensive literature search,
duplicate data abstraction, specific criteria for searching
and analysis) and focused on clinically important pri-
mary outcomes in ICU patients. Nevertheless, we are
aware that our meta-analysis has several limitations,
such as the limited number of trials included to evaluate
different outcomes. In addition, the effect on infections
is driven mostly by the large RCT by Grau-Carmona
et al. (N = 159) [65]. This trial explains 52% of the signal
and is thus an unstable estimate, which increases slightly
after the sensitivity analysis excluding the Hall et al.
study [17] (RR = 0.64; 95% CI, 0.44 to 0.94; P = 0.02;
heterogeneity I2 = 0%). In addition, most of data about
MV days and ICU and hospital LOS were extracted from
the original reports, which may underestimate the aver-
age duration in those cases where LOS of non-survivors
was included in the calculation. Finally, there are two
unpublished abstracts [54,55] from which we could not
obtain sufficient data to include in our meta-analysis.
These factors may limit the reliability of our estimates
and weaken the strength of our conclusions.
Conclusions
In this updated systematic review and meta-analysis, we
demonstrate that parenteral FO-containing LEs in critic-
ally ill patients may be able to significantly reduce the
incidence of infectious complications and also could be
associated with a reduction in the duration of MV and
hospital LOS. Our results are generalizable to patients
receiving some form of artificial nutrition in the ICU
setting. Nevertheless, according to the current literature,
Manzanares et al. Critical Care  (2015) 19:167 Page 13 of 15there is inadequate evidence to give a strong recommen-
dation on the routine use of FO-containing LEs in PN
and/or as a pharmaconutrient strategy in enterally fed
critically ill patients. Additional large-scale and well-
designed RCTs, which should be aimed at confirming
our observations, are required and warranted.Key messages
 Intravenous FO-containing LEs are rich in ω-3
PUFAs, which exhibit anti-inflammatory and
immunomodulatory effects.
 These FO-containing strategies may be able to
significantly reduce the incidence of infectious
complications and also could be associated with a
reduction in the duration of MV and hospital LOS
in critically ill patients.
 FO-containing LEs as pharmaconutrient strategies in
enterally fed patients may be able to reduce
mortality.
 So far, there is inadequate evidence to give a final
recommendation on the use of FO-containing LEs
as a ω-6 fatty acid–reducing strategy in ICU patients
who require PN and/or as a pharmaconutrient
strategy in enterally or orally fed patients.
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